{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:45:36Z","timestamp":1791895536963,"version":"4.3.4"},"reference-count":64,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2023,5,1]]},"abstract":"<jats:sec id=\"ab-doi230006-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Tumor necrosis factor\u2013\u03b1 inhibitors (TNFis) approved to treat several inflammatory diseases are sometimes used off label to treat severe forms of acne that are refractory to conventional therapies. However, use of TNFis can also be followed by acne occurrence, suggesting an association between TNFis and acne. Most of the literature on the topic comprises case reports and series that have not been reviewed in a systematic manner.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-doi230006-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To characterize the demographic characteristics, clinical presentations, treatments, and outcomes of patients receiving TNFis to treat acne and patients who develop acne following treatment of other conditions with TNFis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-doi230006-6\">\n                    <jats:title>Evidence Review<\/jats:title>\n                    <jats:p>A systematic literature review was performed and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses reporting guidelines. PubMed and Web of Science were searched from inception through October 17, 2022. Included studies reported on patients of any sex or age who received TNFis whose treatment was followed by resolution or occurrence of acne. Two independent reviewers screened studies based on predefined criteria and extracted data from each study, which were quantitatively combined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-doi230006-7\">\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>A total of 53 studies reporting on 64 patients who received TNFis for the treatment of acne (n\u2009=\u200947) or who experienced acne after treatment with TNFis for a different condition (n\u2009=\u200917) (mean age, 28.7 years; range, 12-64 years; 6 female individuals [8.8%]) were included. The TNFis used included adalimumab, infliximab, and etanercept. Among the 47 patients treated for acne with TNFis, most had previously received antibiotics (31 [66.0%]) or isotretinoin (32 [68.1%]). Most (44 [93.6%]) experienced partial improvement (25 [53.2%]) or clearance (19 [40.4%]) with very few adverse effects reported (3 [6.4%]). Acne manifested as part of an inflammatory syndrome for 30 patients (63.8%). Among the 17 patients treated TNFis for a different condition followed by the occurrence of acne, only 1 patient (5.9%) reported having a history of acne. Therapy with TNFis was either discontinued (8 [47.1%]) or altered (6 [35.3%]) in most patients due to acne occurrence, typically with improvement in symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-doi230006-8\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>The results of this systematic review suggest that TNFis can be effective in treating refractory acne but can also be associated with the occurrence of acne in certain instances. Further studies elucidating the role that TNF plays in treating and inducing acne could yield insight into off-label TNFi use and acne pathogenesis, potentially guiding clinical care of patients with acne treated or induced by TNFis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamadermatol.2023.0269","type":"journal-article","created":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T11:00:33Z","timestamp":1679050833000},"page":"504","source":"Crossref","is-referenced-by-count":20,"title":["Role of Tumor Necrosis Factor\u2013\u03b1 Inhibitors in the Treatment and Occurrence of Acne"],"prefix":"10.1001","volume":"159","author":[{"given":"Aaron Gabriel W.","family":"Sandoval","sequence":"first","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren T.","family":"Vaughn","sequence":"additional","affiliation":[{"name":"Georgetown University School of Medicine, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer T.","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Boston Children\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Barbieri","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Associate Editor, JAMA Dermatology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"doi230006r1","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1007\/s13555-021-00552-6","article-title":"Updated treatment for acne: targeted therapy based on pathogenesis.","volume":"11","author":"Kurokawa","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"doi230006r2","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000239","article-title":"Paradoxical reactions under TNF-a blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview.","volume":"2","author":"Toussirot","year":"2016","journal-title":"RMD Open"},{"issue":"1","key":"doi230006r3","doi-asserted-by":"publisher","first-page":"104","DOI":"10.4103\/ijdvl.IJDVL_834_16","article-title":"Adalimumab as a successful treatment for acne fulminans and bilateral acute sacroiliitis with hip synovitis complicating isotretinoin therapy.","volume":"84","author":"Dawoud","year":"2018","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"1","key":"doi230006r4","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/pde.v37.1","article-title":"Isotretinoin-induced sacroiliitis: case series of four patients and a systematic review of the literature.","volume":"37","author":"Karadag","year":"2020","journal-title":"Pediatr Dermatol"},{"issue":"4","key":"doi230006r5","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/ced.2015.40.issue-4","article-title":"Acne conglobata and adalimumab: use of tumour necrosis factor-a antagonists in treatment-resistant acne conglobata, and review of the literature.","volume":"40","author":"Yiu","year":"2015","journal-title":"Clin Exp Dermatol"},{"issue":"11","key":"doi230006r6","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1001\/jamadermatol.2013.6678","article-title":"Adalimumab for the treatment of refractory acne conglobata.","volume":"149","author":"Sand","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"2","key":"doi230006r7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1159\/000512032","article-title":"Adalimumab in the management of isotretinoin-induced acne fulminans: report of a case.","volume":"7","author":"Marasca","year":"2021","journal-title":"Skin Appendage Disord"},{"issue":"8","key":"doi230006r8","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1111\/ddg.v17.8","article-title":"A dramatic case of acne fulminans responding to adalimumab.","volume":"17","author":"Miguel","year":"2019","journal-title":"J Dtsch Dermatol Ges"},{"issue":"2","key":"doi230006r9","doi-asserted-by":"publisher","first-page":"7003","DOI":"10.51894\/001c.7003","article-title":"A novel treatment of acne fulminans with adalimumab: a case report.","volume":"3","author":"Rajaii","year":"2018","journal-title":"Spartan Med Res J"},{"issue":"4","key":"doi230006r10","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/ccr3.520","article-title":"Dramatic improvement of severe acne pustolosa after adalimumab in a patient with ulcerative colitis.","volume":"4","author":"Rispo","year":"2016","journal-title":"Clin Case Rep"},{"issue":"6","key":"doi230006r11","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ad.2009.12.026","article-title":"[Efficacy of etanercept in the treatment of acne conglobata].","volume":"101","author":"Vega","year":"2010","journal-title":"Actas Dermosifiliogr"},{"issue":"4","key":"doi230006r12","doi-asserted-by":"publisher","DOI":"10.4172\/2155-9554","article-title":"Good response of acne conglobata to adalimumab in two patients with hidradenitis suppurativa.","volume":"7","author":"Kirthi Jeyarajah","year":"2016","journal-title":"J Clin Exp Dermatol Res"},{"key":"doi230006r13","doi-asserted-by":"publisher","first-page":"S327","DOI":"10.14309\/00000434-200809001-00834","article-title":"Hidradenitis suppurativa, acne conglobata associated with spondyloarthropathy and pyoderma gangrenosum: response to infliximab.","volume":"103","author":"Blachman","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"doi230006r14","first-page":"76","article-title":"Is acne conglobata the opposite spectrum of hidradenitis suppurativa-especially when it responds well to adalimumab?","volume":"30","author":"Tampouratzi","year":"2021","journal-title":"Exp Dermatol"},{"issue":"4","key":"doi230006r15","doi-asserted-by":"publisher","first-page":"418","DOI":"10.2340\/00015555-0451","article-title":"Psoriasis vulgaris associated with acne vulgaris: differential effects of biologicals?","volume":"88","author":"Colsman","year":"2008","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"doi230006r16","doi-asserted-by":"publisher","first-page":"256","DOI":"10.2340\/00015555-0046","article-title":"Severe acne successfully treated with etanercept.","volume":"86","author":"Campione","year":"2006","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"doi230006r17","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1111\/ced.2011.36.issue-6","article-title":"Sustained remission of nodular inflammatory acne after treatment with infliximab.","volume":"36","author":"Schuttelaar","year":"2011","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"doi230006r18","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jaad.2005.06.008","article-title":"Treatment of acne conglobata with infliximab.","volume":"55","author":"Shirakawa","year":"2006","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"doi230006r19","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.jpeds.2004.08.001","article-title":"Abnormal production of tumor necrosis factor (TNF)\u2013alpha and clinical efficacy of the TNF inhibitor etanercept in a patient with PAPA syndrome [corrected].","volume":"145","author":"Cortis","year":"2004","journal-title":"J Pediatr"},{"issue":"6","key":"doi230006r20","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1002\/art.v64.6","article-title":"Brief report: genotype, phenotype, and clinical course in five patients with PAPA syndrome (pyogenic sterile arthritis, pyoderma gangrenosum, and acne).","volume":"64","author":"Demidowich","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"3","key":"doi230006r21","first-page":"452","article-title":"Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome (PAPA syndrome) with E250K mutation in CD2BP1 gene treated with the tumor necrosis factor inhibitor adalimumab.","volume":"30","author":"Lee","year":"2012","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"doi230006r22","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2340\/00015555-1929","article-title":"Recurrent pyoderma gangrenosum and cystic acne associated with leucocyte adhesion deficiency due to novel mutations in ITGB2: successful treatment with infliximab and adalimumab.","volume":"95","author":"Vahlquist","year":"2015","journal-title":"Acta Derm Venereol"},{"issue":"27","key":"doi230006r23","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000187","article-title":"Association of pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) shares genetic and cytokine profiles with other autoinflammatory diseases.","volume":"93","author":"Marzano","year":"2014","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"doi230006r24","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/RHU.0b013e318278b84c","article-title":"Pyoderma gangrenosum, acne conglobata, suppurative hidradenitis, and axial spondylarthritis: efficacy of anti-tumor necrosis factor a therapy.","volume":"18","author":"Bruzzese","year":"2012","journal-title":"J Clin Rheumatol"},{"issue":"4","key":"doi230006r25","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1159\/000515002","article-title":"Successful treatment of coexistent acne fulminans and severe hidradenitis suppurativa with adalimumab.","volume":"7","author":"Kontochristopoulos","year":"2021","journal-title":"Skin Appendage Disord"},{"issue":"3","key":"doi230006r26","first-page":"255","article-title":"Perifolliculitis capitis abscedens et suffodiens treated with anti\u2013tumor necrosis factor\u2013alpha\u2014possible new treatment option.","volume":"26","author":"Sjerobabski Masnec","year":"2018","journal-title":"Acta Dermatovenerol Croat"},{"issue":"8","key":"doi230006r27","doi-asserted-by":"publisher","first-page":"e374","DOI":"10.1111\/jde.v48.8","article-title":"Perifolliculitis capitis abscedens et suffodiens with hidradenitis suppurativa and nodulocystic acne treated with adalimumab.","volume":"48","author":"Kurokawa","year":"2021","journal-title":"J Dermatol"},{"issue":"5","key":"doi230006r28","doi-asserted-by":"publisher","first-page":"S118","DOI":"10.1016\/j.jaad.2004.09.006","article-title":"Acne fulminans with synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome treated with infliximab.","volume":"52","author":"Iqbal","year":"2005","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"doi230006r29","first-page":"444","article-title":"Biologics for rare inflammatory diseases: TNF blockade in the SA PHO syndrome.","volume":"70","author":"Burgemeister","year":"2012","journal-title":"Neth J Med"},{"issue":"3","key":"doi230006r30","first-page":"212","article-title":"Chronic recurrent multifocal osteomyelitis (CRMO) and synovitis acne pustulosis hyperostosis osteitis (SAPHO) syndrome\u2014two presentations of the same disease?","volume":"26","author":"Jelu\u0161ic","year":"2018","journal-title":"Acta Dermatovenerol Croat"},{"issue":"6","key":"doi230006r31","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1080\/14397595.2021.1892264","article-title":"Diagnostic challenge of synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome in pediatric age: a monocentric case series.","volume":"31","author":"Maccora","year":"2021","journal-title":"Mod Rheumatol"},{"issue":"1","key":"doi230006r32","doi-asserted-by":"publisher","first-page":"131","DOI":"10.5021\/ad.2017.29.1.131","article-title":"Infliximab for treatment of synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: a case report.","volume":"29","author":"Hirohata","year":"2017","journal-title":"Ann Dermatol"},{"issue":"1","key":"doi230006r33","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2165\/11593250-000000000-00000","article-title":"Long-term treatment of severe SAPHO syndrome with adalimumab: case report and a review of the literature.","volume":"13","author":"Garcovich","year":"2012","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"doi230006r34","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.jfma.2013.10.001","article-title":"SAPHO syndrome associated with acne conglobata successfully treated with etanercept.","volume":"114","author":"Su","year":"2015","journal-title":"J Formos Med Assoc"},{"issue":"2","key":"doi230006r35","doi-asserted-by":"publisher","first-page":"76","DOI":"10.4274\/turkderm","article-title":"SAPHO syndrome associated with acne fulminans in an adolescent patient.","volume":"53","author":"Aytekin","year":"2019","journal-title":"Turkdem-Turkish Arc Dermatol Venerol"},{"issue":"2","key":"doi230006r36","first-page":"185","article-title":"SAPHO syndrome associated with hidradenitis suppurativa successfully treated with infliximab and methotrexate.","volume":"69","author":"De Souza","year":"2011","journal-title":"Bull NYU Hosp Jt Dis"},{"issue":"1","key":"doi230006r37","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s13052-020-00933-1","article-title":"SAPHO syndrome: the supposed trigger by isotretinoin, the efficacy of adalimumab and the specter of depressive disorder: a case report.","volume":"46","author":"Luzzati","year":"2020","journal-title":"Ital J Pediatr"},{"issue":"5","key":"doi230006r38","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1093\/rheumatology\/keh149","article-title":"SAPHO syndrome treated with pamidronate: an open-label study of 10 patients.","volume":"43","author":"Amital","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"doi230006r39","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/jdv.v33.s6","article-title":"Successful treatment of co-existent SAPHO syndrome and hidradenitis suppurativa with adalimumab and methotrexate.","volume":"33","author":"Genovese","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"doi230006r40","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.22776","article-title":"Synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome diagnosis in adolescent and isotretinoin as a possible serious exacerbating factor.","volume":"14","author":"Shahada","year":"2022","journal-title":"Cureus"},{"issue":"1","key":"doi230006r41","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12969-022-00749-9","article-title":"Tumor necrosis factor inhibitors for pediatric patients with SAPHO syndrome associated with acne conglobata.","volume":"20","author":"Liu","year":"2022","journal-title":"Pediatr Rheumatol Online J"},{"issue":"3","key":"doi230006r42","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1684\/ejd.2017.2990","article-title":"Acne conglobata induced by adalimumab.","volume":"27","author":"Balakirski","year":"2017","journal-title":"Eur J Dermatol"},{"key":"doi230006r43","first-page":"279","article-title":"Acneiform eruption after infliximab and azathioprine.","volume":"39","author":"Moon","year":"2012","journal-title":"J Dermatol"},{"issue":"8","key":"doi230006r44","doi-asserted-by":"publisher","first-page":"e306","DOI":"10.1111\/ijd.2015.54.issue-8","article-title":"Acneiform eruption as a probable paradoxical reaction to adalimumab.","volume":"54","author":"Fern\u00e1ndez-Crehuet","year":"2015","journal-title":"Int J Dermatol"},{"issue":"1","key":"doi230006r45","first-page":"69","article-title":"Acneiform eruption following anti-TNF-alpha treatment: a report of three cases.","volume":"7","author":"Sun","year":"2008","journal-title":"J Drugs Dermatol"},{"issue":"11","key":"doi230006r46","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1111\/jde.v48.11","article-title":"Clinical background of patients with psoriasiform skin lesions due to tumor necrosis factor antagonist administration at a single center.","volume":"48","author":"Mori","year":"2021","journal-title":"J Dermatol"},{"issue":"2","key":"doi230006r47","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.dsi.2011.09.010","article-title":"Concomitant occurrence of acneiform eruption, alopecia areata, and urticaria during adalimumab treatment in a patient with pustulosis palmoplantaris: Case report and literature review.","volume":"30","author":"He","year":"2012","journal-title":"Zhonghua Pifuke Yixue Zazhi"},{"issue":"1","key":"doi230006r48","first-page":"31","article-title":"Etanercept-induced cystic acne.","volume":"94","author":"Kashat","year":"2014","journal-title":"Cutis"},{"issue":"9","key":"doi230006r49","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.18213","article-title":"Infliximab-associated acneiform eruption in a patient with inflammatory bowel disease.","volume":"13","author":"Khatana","year":"2021","journal-title":"Cureus"},{"issue":"6","key":"doi230006r50","doi-asserted-by":"publisher","DOI":"10.1111\/dth.2017.30.issue-6","article-title":"Infliximab-induced acne and acute localized exanthematous pustulosis: case report.","volume":"30","author":"Senila","year":"2017","journal-title":"Dermatol Ther"},{"issue":"1","key":"doi230006r51","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1080\/09546630802155073","article-title":"Infliximab-induced acne: a new case and review of published reports.","volume":"20","author":"Steels","year":"2009","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"doi230006r52","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/(ISSN)1365-2133","article-title":"Infliximab-induced acne: report of a third case.","volume":"158","author":"Sladden","year":"2008","journal-title":"Br J Dermatol"},{"issue":"2","key":"doi230006r53","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/bjd.2007.156.issue-2","article-title":"Infliximab-induced acne: report of two cases.","volume":"156","author":"Bassi","year":"2007","journal-title":"Br J Dermatol"},{"issue":"3","key":"doi230006r54","doi-asserted-by":"publisher","first-page":"AB20","DOI":"10.1016\/j.jaad.2005.11.085","article-title":"Severe nodulocystic acne vulgaris in a patient on infliximab.","volume":"54","author":"Pandya","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"doi230006r55","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2147\/BTT","article-title":"Paradoxical SAPHO syndrome observed during anti-TNFa therapy for Crohn\u2019s disease.","volume":"11","author":"Amano","year":"2017","journal-title":"Biologics"},{"issue":"3","key":"doi230006r56","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/dth.2015.28.issue-3","article-title":"Off-label use of TNF-alpha inhibitors in a dermatological university department: retrospective evaluation of 118 patients.","volume":"28","author":"Sand","year":"2015","journal-title":"Dermatol Ther"},{"issue":"12","key":"doi230006r57","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1002\/ibd.21643","article-title":"Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: experience from a consecutive cohort of inflammatory bowel disease patients.","volume":"17","author":"Baumgart","year":"2011","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"doi230006r58","first-page":"251","article-title":"Sustained efficacy and safety of infliximab in psoriasis: a retrospective study of 73 patients.","volume":"5","author":"Krathen","year":"2006","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"doi230006r59","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.crohns.2013.08.004","article-title":"Tolerability of one hour 10mg\/kg infliximab infusions in inflammatory bowel diseases: a prospective multicenter cohort study.","volume":"8","author":"Babouri","year":"2014","journal-title":"J Crohns Colitis"},{"issue":"2","key":"doi230006r61","doi-asserted-by":"publisher","DOI":"10.1172\/JCI141594","article-title":"Extracellular traps released by antimicrobial TH17 cells contribute to host defense.","volume":"131","author":"Agak","year":"2021","journal-title":"J Clin Invest"},{"issue":"2","key":"doi230006r62","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jid.2017.07.842","article-title":"Phenotype and antimicrobial activity of Th17 cells induced by propionibacterium acnes strains associated with healthy and acne skin.","volume":"138","author":"Agak","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"1","key":"doi230006r63","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2022.2138691","article-title":"Anti-IL-17A blockade did not significantly reduce inflammatory lesions in a placebo-controlled pilot study in adult patients with moderate to severe acne.","volume":"34","author":"Thiboutot","year":"2023","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"doi230006r64","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/jid.2012.387","article-title":"Isotretinoin use and the risk of inflammatory bowel disease: a population-based cohort study.","volume":"133","author":"Alhusayen","year":"2013","journal-title":"J Invest Dermatol"},{"key":"doi230006r60","unstructured":"PubMed. Pyoderma gangrenosum, acne conglobata, suppurative hidradenitis, and axial spondylarthritis: efficacy of anti-tumor necrosis factor a therapy. Accessed October 19, 2022. https:\/\/pubmed-ncbi-nlm-nih-gov.ezp-prod1.hul.harvard.edu\/23188209\/"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2802696\/jamadermatology_sandoval_2023_oi_230006_1692734295.24534.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T11:00:52Z","timestamp":1692788452000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2802696"}},"subtitle":["A Systematic Review"],"short-title":[],"issued":{"date-parts":[[2023,5,1]]},"references-count":64,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2023.0269","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,1]]}}}